Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due
FOSTER CITY, Calif. -- March 28, 2014
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has elected to
settle its conversion obligations in connection with any 1.00% Senior
Convertible Notes due 2014 (the “Notes”) submitted for conversion on or after
February 1, 2014 entirely in cash.
In accordance with the foregoing, Gilead notified Wells Fargo Bank, National
Association, the Trustee for the Notes, that it had designated a “Cash
Percentage” (as defined in the indenture governing the Notes (the
“Indenture”)) of 100% to apply to the “Daily Share Amount” for every “Trading
Day” during the relevant “Conversion Reference Period” (each as defined in the
Indenture) applicable to the Notes.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need. The
company’s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North and South America, Europe and Asia Pacific.
Gilead Sciences, Inc.
Patrick O’Brien, Investors, 650-522-1936
Amy Flood, Media, 650-522-5643
Press spacebar to pause and continue. Press esc to stop.